MAP2K7 and cancer: Before the successful development of KRAS inhibitor Sotorasib, the therapeutic studies for KRAS-mutant cancers focused on targeting downstream effectors in the RAS-RAF-MEK-ERK pathway, such as the MEK inhibitor Trametinib in combination with chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) [47].